Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Due to the increasing number of new promising technologiesfor commercialization from public fundedresearch sectors, two partners, Vesalius Biocapital andthe technology transfer company Ascenion joined theirforces together with the German Federal Ministry ofEducation and Research (BMBF) to create “the Spinnovator”.This project has been provided up to € 40 millionover the coming 5 years for start-up financing. Half of thebudget will be contributed by Vesalius Biocapital, theother half will be provided by the BMBF, further investorscan co-invest.Last but not least, Roche has invested more than € 158million for their location in Penzberg to develop therapeuticproteins. In June 2011, Roche inaugurated theirinvestment project „TP-Expand“.RevenuesFor reasons of comparison, the figure to the left showsthe business data published by Bavaria’s biotechnologycompanies listed at the stock exchange. Their salesreported for 2011 amount to € 174.8 million, a resultthat is approximately the same as that of last year(2010: € 179.3 million). Remarkable is the share of MorphoSysAG in this respect which is more than € 100million, an all-time high for this company in 2011.Taken together, the sales figures of all but only Bavarianbiotech companies (SMEs) thus show a clear upwardtrend to 2010 with more than € 510 million and a plus ofabout 10% (figure to the right).The major part of thisincrease was generated by private biotech companies.Still a major share of revenues is invested in R&D inBiotech SME 2011: approximately 50% or more than €260 million.SummaryIn the past years, the Bavarian biotechnology sectorshowed further signs of stabilisation and consilidation.An increase in the number of employees of 30 % since2006, stable growth rates almost every year in terms ofsales, and an unbroken technology leadership whichattracts the most famous global companies are definitelypositive signs for Bavarian biotech companies.The attractiveness of excellence in science leading toapplied and translational medicine in innovative fieldslike “personalized medicine” is already paying off – notonly for investors and entrepreneurs but for the societyand finally the patient.Total sales in 2011 for the majority of companies thatare not listed can only be roughly estimated at around€ 340 million, based on the reported figures (65% ofbiotech SMEs).REVENUES TOTAL IN MIO. €,ALL BIOTECH SME TOGETHER20112010REVENUES TOTAL IN MIO. €, LISTED COMPANIES (SME)200620072008 200920102011161 154 185 183 180 175470 51526